Anatomical and functional results of surgical treatment of familial exudative vitreoretinopathy in children

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Familial exudative vitreoretinopathy (FEVR) is a rare hereditary disease characterized by abnormal angiogenesis, presence of avascular zones on the periphery of the retina, and clinical manifestations ranging from an asymptomatic course to total retinal detachment. Surgical interventions are performed to eliminate vitreoretinal traction, epiretinal membranes, and retinal detachment. Studies of the surgical treatment outcomes of patients with FEVR are limited and findings are ambiguous

AIM: To analyze surgical treatment outcomes of different stages of FEVR in childhood.

MATERIAL AND METHODS: From January 2012 to October 2021 at the Helmholtz National Medical Research Center of Eye Diseases, surgical treatment was performed in 35 eyes of 33 patients aged 11 months–15 years (average, 7 years). The effectiveness of treatment was evaluated 1–2 months after the treatment, and patients were examined every 3–6 months for 1–5 years (average 2 years).

RESULTS: Аfter the primary surgery, a decrease in retinal traction in the posterior pole and periphery was achieved in all cases. Complete and incomplete reattachment was achieved in 30% and 70% of the eyes at stage 3 and in 12.5% and 87.5% of the eyes at stage 4, respectively. The long-term effectiveness rates of the intervention in stages 2, 3 (including complete and incomplete reattachment), and 4 were 100%, 87.5%, and 73.3%, respectively.

Increases in the best-corrected visual acuity (BCVA) were observed in 83%, 50%, and 28.6% of the eyes in stages 2, 3, and 4, respectively. In other cases, successful surgical treatment allowed the preservation of visual functions. During the follow-up, visual acuity of 0.1 or more was maintained in 100%, 85.7%, and 36% of the eyes at stages 2, 3, and 4 of FEVR, respectively.

CONCLUSION: Аnatomical and functional results of surgical treatment of FEVR correlate with the disease stage: the efficiency is greater in stage 2, and it was organ-preserving surgery in stage 5. To increase the effectiveness of treatment, early diagnosis of FEVR, laser coagulation of avascular zones, and active vessels are necessary, which makes it possible to stop the progression of the early stages of FEVR in 70%–100% of cases and enables regular monitoring of patients for the timely detection of indications for additional laser coagulation or surgical intervention.

Full Text

Restricted Access

About the authors

Ekaterina V. Denisova

Helmholtz National Medical Research Center of Eye Diseases

Author for correspondence.
Email: deale_2006@inbox.ru
ORCID iD: 0000-0003-3735-6249
SPIN-code: 4111-4330

MD, Cand. Sci. (Med.)

Russian Federation, Moscow

Elizaveta А. Geraskina

Helmholtz National Medical Research Center of Eye Diseases

Email: slinko.amalgam@yandex.ru
ORCID iD: 0000-0002-5306-2534

graduate student

Russian Federation, Moscow

Ludmila А. Katargina

Helmholtz National Medical Research Center of Eye Diseases

Email: katargina@igb.ru
ORCID iD: 0000-0002-4857-0374

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Natalya A. Osipova

Helmholtz National Medical Research Center of Eye Diseases

Email: natashamma@mail.ru
ORCID iD: 0000-0002-3151-6910
SPIN-code: 5872-6819

MD, Cand. Sci. (Med)

Russian Federation, Moscow

References

  1. Benson WE. Familial exudative vitreoretinopathy. Trans Am Ophthalmol Soc. 1995;93:473–521.
  2. Shukla D, Singh J, Sudheer G, et al. Familial exudative vitreoretinopathy (FEVR). Clinical profile and management. Indian J Ophthalmol. 2003;51(4):323–328.
  3. Hocaoglu M, Karacorlu M, Muslubas IS, et al. Anatomical and functional outcomes following vitrectomy for advanced familial exudative vitreoretinopathy: a single surgeon’s experience. Br J Ophthalmol. 2017;101(7):946–950. doi: 10.1136/bjophthalmol-2016-309526
  4. Ikeda T, Fujikado T, Tano Y, et al. Vitrectomy for rhegmatogenous or tractional retinal detachment with familial exudative vitreoretinopathy. Ophthalmology. 1999;106(6):1081–1085. doi: 10.1016/S0161-6420(99)90268-3
  5. El-Khoury S, Clement A, Chehaibou I, et al. Outcome and risk factors of vitreoretinal surgery in pediatric patients with familial exudative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 2020;258(8):1617–1623. doi: 10.1007/s00417-020-04712-w
  6. Pendergast SD, Trese MT. Familial exudative vitreoretinopathy, results of surgical management. Ophthalmology. 1998;105(6):1015–1023. doi: 10.1016/S0161-6420(98)96002-X
  7. Yamane T, Yokoi T, Nakayama Y, et al. Surgical outcomes of progressive tractional retinal detachment associated with familial exudative vitreoretinopathy. Am J Ophthalmol. 2014;158(5):1049–1055. doi: 10.1016/j.ajo.2014.08.009
  8. Kashani AH, Brown KT, Chang E, et al. Diversity of retinal vascular anomalies in patients with familial exudative vitreoretinopathy. Ophthalmology. 2014;121(11):2220–2227. doi: 10.1016/j.ophtha.2014.05.029

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Patient G., familial exudative vitreoretinopathy 2A, epiretinal membrane in the posterior pole: а–с — before threatment, macular thickness 733 microns, best corrected visual acuity (BCVA) 0,1; d–f — after threatment: macular thickness 354 microns, BCVA 0,8; a, d — photo of the fundus; b, e — optical coherence tomography (OCT) of the optic disc; c, f — OCT of the macula.

Download (315KB)
3. Fig. 2. Patient М., familial exudative vitreoretinopathy 3A: а–b — epiretinal membrane in the posterior pole, macular hole with a diameter of 2274 microns, existing for 3 years before threatment, best corrected visual acuity (BCVA) 0,3; c, d — after threatment: the hole is closed, BCVA 0,15; a, c — photo of the fundus; b, d — optical coherence tomography of the macular zone.

Download (260KB)
4. Fig. 3. Patient A., familial exudative vitreoretinopathy 3B, original fundus photo: a — before threatment, epiretinal membrane in the posterior pole with traction; b, c — after threatment, decrease of traction of the posterior pole, best corrected visual acuity 0,3–0,4 (has not changed).

Download (154KB)
5. Fig. 4. Patient L., familial exudative vitreoretinopathy 3B, original fundus photo: a — after threatment, decrease of traction of the posterior pole, height and area of retinal detachment, increase of best corrected visual acuity (BCVA) from 0,01 to 0,05; b — after 1 year, resorption of subretinal exudate, BCVA 0,03.

Download (124KB)
6. Fig. 5. Patient К., familial exudative vitreoretinopathy 4А, original fundus photo: a, b — before threatment: epiretinal fibrosis, retinal fold from optic disc to temporal perifery, best corrected visual acuity (BCVA) 0,02; c — after threatment: decrease of traction of the posterior pole and height of fold, BCVA 0,01.

Download (133KB)
7. Fig. 6. Patient R., familial exudative vitreoretinopathy 4B, original fundus photo: a — before threatment, epiretinal fibrosis and subretinal exudation; b — 3 years after threatment: epiretinal reproliferation, best corrected visual acuity (BCVA) 0,05; c — after second surgery, epiretinal reproliferation, BCVA 0,05.

Download (157KB)
8. Fig. 7. Best corrected visual acuityof eyes with familial exudative vitreoretinopathy before and after surgery threatment (in the columns the number of eyes are indicated..

Download (120KB)

Copyright (c) 2023 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86503 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80630 от 15.03.2021 г
.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies